Tango Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TNGX | IDYA | RLAY | SNDX | 688382.SS | 2256.HK | |
|---|---|---|---|---|---|---|
| Market cap | 3.91B | 3.12B | 3.95B | 940.80M | 8.38B | 5.03B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -13.8 | -7.9 | -11.0 | -14.4 | -43.8 | -24.1 |
| Price/book | 3.8 | 2.9 | 5.5 | -54.7 | 6.6 | 2.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +189.39% | +8.41% | +176.11% | −28.86% | −48.70% | −54.94% |
| Today | +0.04% | +3.29% | +3.38% | −26.87% | +4.33% | +6.85% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All TNGX news ›Tango and Erasca launch Phase 1/2 trial combining vopimetostat and ERAS-0015 for pancreatic and lung cancers
Tango Therapeutics and Erasca have started a Phase 1/2 clinical trial testing the combination of oral PRMT5 inhibitor vopimetostat with pan-RAS molecular glue ERAS-0015. The trial targets patients with MTAP-deleted pancreatic ductal…
Tango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference
Rising Dragon Acquisition Corp. and HZJL Cayman Limited Announce Mutual Termination of Merger Agreement Shopify Sustains Rapid Growth with Revenue Up 32% and Free Cash Flow Margin of 22% Cipher, a Prosegur Company, and BIO-key Announce…
Tango Therapeutics (TNGX) – Investment Analysts’ Weekly Ratings Changes
Posted by Tristan Rich on Nov 3rd, 2026 Several analysts have recently updated their ratings and price targets for Tango Therapeutics (NASDAQ: TNGX): Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last posted its quarterly earnings…
Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data And Pathway Advancement Clarity
Tango Therapeutics earns a Buy upgrade after strong PDAC trial data. - Tango Therapeutics upgraded from 'Hold' to 'Buy' following strong phase 1/2 data for vopimetostat + RASONQUE in MTAP-del, 2nd-line/3rd-line RAS-mutant PDAC. - Company's…
Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is Saying
Tango Therapeutics offers an 82% ORR and notable durability in MTAP-deleted/RAS-mutant pancreatic cancer. Read more on TNGX stock here. - Tango Therapeutics offers an 82% ORR and notable durability in MTAP-deleted/RAS-mutant pancreatic…
Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer - Slideshow
2026-10-27. The following slide deck was published by Tango Therapeutics, Inc. The following slide deck was published by Tango Therapeutics, Inc. in conjunction with this event.
Tango Therapeutics Stock Tumbles 16% Despite 82% Response Rate in Pancreatic Cancer Combo Trial at ESMO
NEW YORK — Tango Therapeutics shares fell more than 16% in early trading Friday. The biotech company presented updated results for its pancreatic cancer drug combination at a major medical meeting, but investors sold the stock after a…
Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug
Allison Gatlin covers biotechnology, pharmaceuticals and medical technology. She also oversees coverage of top-performing companies for Investor's Business Daily's The New America page. Allison has worked for Investor's Business Daily…
Tango Therapeutics, Inc. Announces Management Appointments
Tango Therapeutics, Inc. announced that it appointed Fatma Ocak to the role of Chief Commercialization Officer, effective August 17, 2026. In this role, Ms. Ocak will oversee all aspects of launch... announced that it appointed Fatma Ocak…
Certain Pre-Funded Warrants of Tango Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2026.
These Pre-Funded Warrants will be under lockup for 60 days starting from 9-JUN-2026 to... Certain Pre-Funded Warrants of Tango Therapeutics, Inc are subject to a Lock-Up Agreement Ending
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com6
- seekingalpha.com3
- stocktitan.net2
- themarketsdaily.com2
- ibtimes.com.au1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 18 articles, not a forecast.